• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » DynaCirc CR

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

DynaCirc CR

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    DynaCirc CR, a once-a-day calcium channel blocker, has been approved for the treatment of hypertension. Developed by Sandoz Research in collaboration with ALZA Corporation, DynaCirc CR is available in 5 mg and 10 mg controlled release tablets. The new formulation is Novartis’ first launch of a line extension and offers continuous reduction of blood pressure throughout a 24 hour period. DynaCirc CR has been demonstrated to be safe in a broad range of patients, including elderly, really impaired and diabetic patients, as well as patients with underlying cardiovascular conditions.

    Mechanism of Action

    Isradipine, the active ingredient in DynaCirc CR, is a potent intermediate-acting dihydropyridine calcium antagonist.

    DynaCirc CR achieves its once-a-day dosing regimen through the use of osmotic controlled release technology developed by ALZA Corporation in Palo Alto, California. Known as OROS, OSMOTIC THERAPEUTIC SYSTEM, the system is based on a semipermeable membrane surrounding an osmotically active core. The core is composed of two layers, an active layer containing the drug and a pharmacologically inert, but osmotically active, push layer.

    After ingestion, the tablet overcoating is quickly dissipated in the gastrointestinal tract allowing water to enter the tablet through the semipermeable membrane. The polyethylene oxide polymer swells in the osmotic push layer and expands against the active drug layer releasing an essentially constant dose of isradipine as a fine suspension.

    Literature References

    (1) Cohen JD, Carr AA, Blecker D, et al. DYNAMICS trial of isradipine in hypertension with and without coexisting diseases. Cline Geriatr. 1994;2:36-52.

    (2) Marcus AO, Antihypertensive therapy with the calcium channel blocker isradipine; an appropriate choice for the diabetic patient with hypertension, Review. Curr Ther Res, 1993;54:763-778.

    (3) Berg KJ, Holdaas H, Endresen L, et al. Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients. Nephrol Dial Transplant. 1991;6:725-730.

    (4) Francischetti EA, de Silva IB, Fagundes VG. Effects of long-term administration of isradipine on renal hemodynamics and sodium metabolism. J Cardiovasc Pharmacol. 1992;19 (supp 3):S90-92.

    (5) Persson B, Andersson OK, Wysocki M, et al. Renal and hemodynamic effects of isradipine in essential hypertension. Am J Med, 1989;86 (supp 4A):60-64.

    (6) Grossman E, Messerli FH, Oren S, et al. Cardiovascular effects of isradipine in essential hypertension. Am J. Cardiol. 1991;68:65-70 SOURCE Novartis Pharmaceuticals Corporation.

    Approval Date: 1997-02-01
    Company Name: Novartis
    Back to Listings

    Upcoming Events

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing